CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01180959
NCT01180959Phase 2Completed
CompareCT.gov

A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Received First-line Sorafenib Therapy (AVF4572)

M.D. Anderson Cancer Center·interventional·Posted Aug 12, 2010·Updated Nov 7, 2022

In Brief

A Phase 2 clinical trial evaluating Bevacizumab and Erlotinib for Liver Cancer. Completed, enrolled 45 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if the combination of AvastinTM (bevacizumab) and Tarceva (erlotinib hydrochloride) can help to control advanced liver cancer. The safety of this drug combination will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer
CountriesUnited States
CollaboratorsGenentech, Inc., OSI Pharmaceuticals

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 12, 2010
Enrollment StartApr 14, 2011
Primary CompletionMay 19, 2021
TodayJul 2, 2026
Enrollment to primary: 10.1 yearsPosted 15.9 years ago

Interventions

Bevacizumabdrug

10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes

Erlotinibdrug

150 mg by mouth once a day.